Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004197 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Study locations
NCT00004197: Completed Phase 2 study of Lymphoma, sponsored by University of Nebraska.
NCT00004197 is a Phase 2 study of Lymphoma that has completed, run by University of Nebraska. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004197, a Phase 2 study of Lymphoma, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial of vaccine therapy plus sargramostim following chemotherapy in treating patients who have previously untreated aggressive non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG doxorubicin hydrochloride
- BIOLOGICAL sargramostim
- BIOLOGICAL keyhole limpet hemocyanin
- BIOLOGICAL tumor cell-based vaccine therapy
Study Locations (2)
California
- Stanford University Medical Center - Stanford
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-06-25 |
| Est. Completion | 2003-11-20 |
| Phase | Phase 2 |
What the finished NCT00004197 record still lists
NCT00004197 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00004197 reports a single indexed study location in California, Nebraska.
Frequently Asked Questions
What is clinical trial NCT00004197 about?
NCT00004197 is a clinical study titled "Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone mar...
What is the current status of trial NCT00004197?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-06-25. Estimated completion is 2003-11-20.
What conditions does trial NCT00004197 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00004197?
The interventions under investigation include: cyclophosphamide (DRUG), doxorubicin hydrochloride (DRUG), sargramostim (BIOLOGICAL), keyhole limpet hemocyanin (BIOLOGICAL), tumor cell-based vaccine therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004197?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004197 being conducted?
This trial has 2 study locations across California, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI